BY HANS ALBRECHT
October 17, 2025
My dad loved Neil Young.
So when I was growing up, I heard the song Alabama a lot.
And there’s one line that sticks out as I look over our momentum, income and AI expert Hans Albrecht’s piece today…
“…the devil fools with the best laid plans.”
Last week I told you about Hans’ proprietary Market TemperatureIndicator (MTI) he uses to spot stocks poised to charge forward.
I also mentioned how his indicator has a “damper” that starts to discount stocks when a big trend change looks likely.
Well, with the market’s big ups and downs since last Friday, the MTI has put the kibosh on most trades it would typically highlight.
So today, when Hans tells you about a stock he loves and one he hates, he’s going to rely on the experience he’s gathered over the last 29years as a pro trader. And he’s going to tell you the underlying fundamentals and stories powering them.
These stories… the future of technology.
Have a read:
AI + Genomics = The Next Revolution
Some of the most transformative advances in AI aren’t in software — they’re in biology.
As compute costs plunge 75–85% a year, scientists can now model the human body as a living data network. This fusion of AI and genomics is unlocking faster drug discovery, earlier detection, and even the possibility of true cures.
Example: Meta’s ESM3 model didn’t just predict biology – it created it. By simulating hundreds of millions of years of evolution digitally, ESM3 designed esmGFP, a brand-new fluorescent protein that glows bright green under UV light — despite no such sequence existing in nature. It’s the first time an AI has invented a functional biomolecule from scratch.
The implications are massive: AI can now generate enzymes, materials, and therapeutics evolution never produced. This is programmable biology that rewrites what’s possible in medicine and materials science.
For funds like Ark Genomic Revolution ETF (ARKG), this is where AI stops studying life and starts designing it.
With innovation costs collapsing and valuations still modest, ARKG offers exposure to what could be the decade’s most explosive theme: the AI-powered genomics revolution.
It’s hard to pick a winner here so a broader but thematic name like ARKG hits the mark.
The Problem With Quantum Computing
Quantum computing has sprinted up the hype curve, but the physics haven’t caught up to the prices. Stocks like Rigetti Computing Inc (RGTI) are trading as if commercialization is imminent, yet quantum remains deep in the lab.
It could be another 20 or 30 years before it gets out.
We’re at the “innovation trigger” stage of the Gartner hype cycle – the point where excitement runs well ahead of reality. Unlike AI, which is already producing measurable productivity gains, quantum’s progress is mostly theoretical, with few proven use cases.
Take one of the most recent breakthroughs as an example: Quantum computers are powered by something called a Qubit. The problem? They only stay stable for about 400 milliseconds.
The breakthrough? A Paris based quantum startup figured out how to make a Qubit last around an hour.
That’s a major breakthrough. But it’s far from what’s needed for commercial adoption.
There’s no doubt quantum will one day revolutionize computing, encryption, and materials science – but we’re decades away.
Markets have priced in a decade of future potential today, leaving RGTI and peers looking more like science projects than investable businesses.
To your health and income,
Hans
Want To Watch Us Live?
Add Our Free Events To Your Calendar By Clicking Your Email Icon Below!
